Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
The Breast CMV Study
NCT07383649Phase 2Recruiting
- Sponsor
- Houston Methodist Research Institute
- Start
- Jul 2026
- Primary completion
- May 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of valganciclovir in breast cancer, brain metastases and cytomegalovirus infection (CMV), sponsored by Houston Methodist Research Institute. Primary endpoint: Objective Response Rate at 6 weeks. Started Jul 2026; status: recruiting.
02
Drugs
valganciclovir
03
Conditions
breast cancerbrain metastasescytomegalovirus infection (CMV)
Beyond the preview
Go deeper on NCT07383649.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07383649.